Small molecule · Inhibitor of ribonucleotide reductase · developed by Boundless Bio
BBI-825 is an orally available small molecule that selectively inhibits ribonucleotide reductase, the enzyme that converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates for DNA synthesis. By reducing the deoxyribonucleotide pool, it disrupts DNA synthesis and cell cycle progression. It is studied in multiple solid tumors, including triple negative breast cancer, ovarian, endometrial, head and neck, and small cell lung cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05827614 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Terminated | BOLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anogenital CancerCervical Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)ER+ Breast CancerHead and Neck (HNSCC)High Grade Endometrial CarcinomaHigh Grade Serous Ovarian CarcinomaLeiomyosarcoma (LMS)Pancreatic Cancer MetastaticSmall Cell Lung CancerTriple Negative Breast Cancer (TNBC)Undifferentiated Pleomorphic Sarcoma (UPS)
See BOLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BOLD catalysts and pipeline →